20.500.12556/RUL-144672 Detrimental effect of various preparations of the human amniotic membrane homogenate on the 2D and 3D bladder cancer in vitro models Despite being among the ten most common cancers with high recurrence rates worldwide, there have been no major breakthroughs in the standard treatment options for bladder cancer in recent years. The use of a human amniotic membrane (hAM) to treat cancer is one of the promising ideas that have emerged in recent years. This study aimed to investigate the anticancer activity of hAM homogenate on 2D and 3D cancer models. We evaluated the effects of hAM homogenates on the human muscle invasive bladder cancer urothelial (T24) cells, papillary cancer urothelial (RT4) cells and normal porcine urothelial (NPU) cells as well as on human mammary gland nontumorigenic (MCF10a) cells and low-metastatic breast cancer (MCF7) cells. After 24 h, we observed a gradual detachment of cancerous cells from the culture surface, while the hAM homogenate did not affect the normal cells. The most pronounced effect hAM homogenate had on bladder cancer cells; however, the potency of their detachment was dependent on the treatment protocol and the preparation of hAM homogenate. We demonstrated that hAM homogenate significantly decreased the adhesion, growth, and proliferation of human bladder invasive and papillary cancer urothelial cells and did not affect normal urothelial cells even in 7-day treatment. By using light and electron microscopy we showed that hAM homogenate disrupted the architecture of 2D and 3D bladder cancer models. The information provided by our study highlights the detrimental effect of hAM homogenate on bladder cancer cells and strengthens the idea of the potential clinical application of hAM for bladder cancer treatment. cancer urothelium 2D and 3D in vitro models light and electron microscopy proliferation cell cycle rak sečnega mehurja urotelij 2D in 3D in vitro modeli elektronski mikroskop proliferacija urologija true false true Angleški jezik Slovenski jezik Članek v reviji 2023-03-07 14:39:15 2023-03-07 14:39:16 2023-03-08 03:33:19 0000-00-00 00:00:00 2021 0 0 19 str. Vol. 9, art. 690358 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.6 2296-4185 10.3389/fbioe.2021.690358 69118467 fbioe-09-690358.pdf fbioe-09-690358.pdf 1 8DA335C81329B4AB3D0FE859E9E5EA45 0c7f6e87190d70a4548c7bba2f98a4a082517c42f0831dd4226ac8d38ae5b8ac a07a60ab-bcef-11ed-a314-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=167131 https://www.frontiersin.org/articles/10.3389/fbioe.2021.690358/full 1 6cef67bf-bced-11ed-a314-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=167130 Medicinska fakulteta 0 0 0